시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
브루가다 증후군 시장 규모, 점유율, 성장 분석 : 진단별, 약제별, 치료별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Brugada Syndrome Market Size, Share, Growth Analysis, By Diagnosis (Electrocardiogram, Electrophysiology (Ep) Test), By Drugs (Antiarrhythmic drugs, Psychotropic drugs), By Treatment, By End user, By Region - Industry Forecast 2025-2032
상품코드 : 1630679
리서치사 : SkyQuest
발행일 : 2025년 01월
페이지 정보 : 영문 158 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,828,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 9,158,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,487,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 브루가다 증후군 시장 규모는 2023년에 14억 달러로 평가되며, 2024년 14억 8,000만 달러에서 2032년에는 23억 1,000만 달러로 성장하며, 예측 기간 중(2025-2032년) CAGR 5.7%로 성장할 전망입니다.

세계의 브루가다 증후군 시장은 심장의 전기적 시스템을 교란시키는 이 희귀 유전질환의 유병률이 증가함에 따라 심혈관 건강에 큰 변화가 일어나고 있습니다. 유전자 검사 기술의 발전과 맞춤형 의료에 대한 관심이 높아짐에 따라 인지도가 높아지면서 더 나은 진단 및 치료 전략이 개발되고 있습니다. 이러한 긍정적인 변화에도 불구하고 조기 발견과 질환의 복잡성 이해에 대한 과제는 여전히 남아 있으며, 이는 현재 진행 중인 연구 구상을 촉진하고 있습니다. 경쟁 환경의 특징은 제약회사, 진단 실험실, 의료기기 제조업체 간의 협력으로, 이들 모두 브루가다 증후군 관리에서 충족되지 않은 요구를 충족시키기 위해 노력하고 있다는 점입니다. 전반적으로 이해관계자들이 협력하여 환자의 결과를 개선하고 치료 옵션을 넓히기 위해 노력하는 이 시장은 유망한 시장입니다.

목차

서론

조사 방법

개요

시장 역학과 전망

주요 시장 인사이트

브루가다 증후군 시장 규모 : 진단별

브루가다 증후군 시장 규모 : 약물별

브루가다 증후군 시장 규모 : 치료별

브루가다 증후군 시장 규모 : 최종사용자별

브루가다 증후군 시장 규모

경쟁 정보

주요 기업 개요

결론과 권장사항

KSA
영문 목차

영문목차

Global Brugada Syndrome Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.48 billion in 2024 to USD 2.31 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The global Brugada syndrome market is experiencing significant transformation within cardiovascular health due to the rising prevalence of this rare genetic disorder that disrupts the heart's electrical system. Enhanced awareness is driving better diagnosis and treatment strategies, bolstered by advancements in genetic testing technologies and an increasing emphasis on personalized medicine. Despite these positive shifts, challenges in early detection and comprehension of the syndrome's intricacies persist, prompting ongoing research initiatives. The competitive landscape is marked by collaboration among pharmaceutical companies, diagnostic labs, and medical device manufacturers, all striving to meet the unmet needs in managing Brugada syndrome. Overall, the market shows promise as stakeholders work together to improve patient outcomes and expand treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Brugada Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Brugada Syndrome Market Segmental Analysis

Global Brugada Syndrome Market is segmented by Diagnosis, Drugs, Treatment, End user and region. Based on Diagnosis, the market is segmented into Electrocardiogram, Electrophysiology (Ep) Test and Genetic Testing. Based on Drugs, the market is segmented into Antiarrhythmic drugs, Psychotropic drugs, Anesthetics/analgesics and Others. Based on Treatment, the market is segmented into Implantable Cardioverter-Defibrillator and Drug Therapy. Based on End user, the market is segmented into Hospitals, Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Brugada Syndrome Market

The Brugada Syndrome market is significantly driven by the growing awareness and comprehension of the condition among both healthcare providers and the general public. As knowledge about Brugada syndrome expands, it leads to earlier diagnosis and timely intervention, which ultimately enhances patient outcomes. This collective understanding encourages medical professionals to recognize the symptoms more effectively and promotes education initiatives aimed at informing the public. Consequently, such advancements not only improve the rate of detection but also empower patients with knowledge about their condition, fostering a more proactive approach to management and treatment in the expanding Brugada syndrome market.

Restraints in the Global Brugada Syndrome Market

A significant constraint in the global Brugada Syndrome market is the insufficient understanding of its underlying mechanisms. This complex genetic disorder presents challenges in achieving accurate diagnoses and developing targeted treatment options. The lack of comprehensive knowledge hampers advancements in research and impedes effective strategies for managing the condition. As a result, healthcare professionals may struggle to identify the syndrome promptly or to provide the most appropriate therapies, ultimately limiting market growth and innovation in this area. Overcoming this limitation is crucial for improving patient outcomes and advancing the overall understanding of Brugada Syndrome.

Market Trends of the Global Brugada Syndrome Market

The Global Brugada Syndrome market is witnessing a notable trend towards the rising emphasis on genetic testing, fueled by an enhanced understanding of the genetic underpinnings of the condition. Advances in genomic technologies have paved the way for more precise and accessible genetic analyses that identify mutations linked to Brugada syndrome. Concurrently, the integration of artificial intelligence (AI) in electrocardiogram (ECG) analysis is transforming diagnosis, enabling automated detection of subtle cardiac abnormalities that may otherwise go unnoticed. This confluence of genetic insights and technological innovations is poised to improve patient outcomes and drive continued growth in the Brugada Syndrome market.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Brugada Syndrome Market Size by Diagnosis & CAGR (2025-2032)

Global Brugada Syndrome Market Size by Drugs & CAGR (2025-2032)

Global Brugada Syndrome Market Size by Treatment & CAGR (2025-2032)

Global Brugada Syndrome Market Size by End user & CAGR (2025-2032)

Global Brugada Syndrome Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기